Case 2. Response to erlotinib after failure of gefitinib in a patient with advanced non-small-cell lung carcinoma

被引：33

作者：

Garfield, DH ^{[1
]}

机构：

[1] Univ Colorado, Hlth Sci Ctr, Dept Med, Aurora, CO USA

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2005年 / 23卷 / 30期

关键词：

D O I：

10.1200/JCO.2005.02.4471

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

[No abstract available]

引用

页码：7738 / 7740

页数：3

共 13 条

[1] Phase I safety, pharmacokinetic, and pharmacodynamic trial of ZD1839, a selective oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with five selected solid tumor types [J].

Baselga, J ;

Rischin, D ;

Ranson, M ;

Calvert, H ;

Raymond, E ;

Kieback, DG ;

Kaye, SB ;

Gianni, L ;

Harris, A ;

Bjork, T ;

Averbuch, SD ;

Feyereislova, A ;

Swaisland, H ;

Rojo, F ;

Albanell, J .

JOURNAL OF CLINICAL ONCOLOGY, 2002, 20 (21) :4292-4302

[2] United States Food and Drug Administration drug approval summary: Gefitinib (ZD1839; Iressa) tablets [J].

Cohen, MH ;

Williams, GA ;

Sridhara, R ;

Chen, G ;

McGuinn, WD ;

Morse, D ;

Abraham, S ;

Rahman, A ;

Liang, CY ;

Lostritto, R ;

Baird, A ;

Pazdur, R .

CLINICAL CANCER RESEARCH, 2004, 10 (04) :1212-1218

[3] The current situation:: Erlotinib (Tarceva®) and gefitinib (Iressa®) in non-small cell lung cancer [J].

Comis, RL .

ONCOLOGIST, 2005, 10 (07) :467-470

[4] Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer [J].

Fukuoka, M ;

Yano, S ;

Giaccone, G ;

Tamura, T ;

Nakagawa, K ;

Douillard, JY ;

Nishiwaki, Y ;

Vansteenkiste, J ;

Kudoh, S ;

Rischin, D ;

Eek, R ;

Horai, T ;

Noda, K ;

Takata, I ;

Smit, E ;

Averbuch, S ;

Macleod, A ;

Feyereislova, A ;

Dong, RP ;

Baselga, J .

JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (12) :2237-2246

[5] Epidermal growth factor receptor inhibitors in the treatment of non-small-cell lung cancer [J].

Giaccone, G .

JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (14) :3235-3242

[6] Phase I and pharmacologic study of OSI-774, an epidermal growth factor receptor tyrosine kinase inhibitor, in patients with advanced solid malignancies [J].

Hidalgo, M ;

Siu, LL ;

Nemunaitis, J ;

Rizzo, J ;

Hammond, LA ;

Takimoto, C ;

Eckhardt, SG ;

Tolcher, A ;

Britten, CD ;

Denis, L ;

Ferrante, K ;

Von Hoff, DD ;

Silberman, S ;

Rowinsky, EK .

JOURNAL OF CLINICAL ONCOLOGY, 2001, 19 (13) :3267-3279

[7] Increased epidermal growth factor receptor gene copy number detected by fluorescence in situ hybridization associates with increased sensitivity to gefitinib in patients with bronchioloalveolar carcinoma subtypes: A Southwest Oncology Group Study [J].

Hirsch, FR ;

Varella-Garcia, M ;

McCoy, J ;

West, H ;

Xavier, AC ;

Gumerlock, P ;

Bunn, PA ;

Franklin, WA ;

Crowley, J ;

Gandara, DR .

JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (28) :6838-6845

[8] Epidermal growth factor receptor mutations in non-small-cell lung cancer:: Implications for treatment and tumor biology [J].

Jänne, PA ;

Engelman, JA ;

Johnson, BE .

JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (14) :3227-3234

[9] Approval summary for erlotinib for treatment of patients with locally advanced or metastatic non-small cell lung cancer after failure of at least one prior chemotherapy regimen [J].

Johnson, JR ;

Cohen, M ;

Sridhara, R ;

Chen, YF ;

Williams, GM ;

Duan, J ;

Gobburu, J ;

Booth, B ;

Benson, K ;

Leighton, J ;

Hsieh, LS ;

Chidambaram, N ;

Zimmerman, P ;

Pazdur, R .

CLINICAL CANCER RESEARCH, 2005, 11 (18) :6414-6421

[10] Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer - A randomized trial [J].

Kris, MG ;

Natale, RB ;

Herbst, RS ;

Lynch, TJ ;

Prager, D ;

Belani, CP ;

Schiller, JH ;

Kelly, K ;

Spiridonidis, H ;

Sandler, A ;

Albain, KS ;

Cella, D ;

Wolf, MK ;

Averbuch, SD ;

Ochs, JJ ;

Kay, AC .

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2003, 290 (16) :2149-2158

← 1 2 →